Recombinant human insulin-like growth factor-I increases forearm blood flow.

Copeland KC, Nair KS

The Journal of clinical endocrinology and metabolism1 Jul 1994Cited by 55 (Europe PMC)

PMID8027233DOI10.1210/jcem.79.1.8027233PepBankPUB-08027233

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanNon-randomized trialEfficacy outcome
In healthy volunteers, low-dose IGF-I infusion did not affect forearm blood flow compared with saline control.
In plain wordsIn healthy volunteers, low-dose IGF-I infusion did not affect forearm blood flow compared with saline control.
Peptide
IGF-1 (mecasermin)
Outcome
No significant changeForearm blood flow
Study
n = 11
Comparator
Saline control
Outcome group
Vascular function · Cardiovascular
Studied dose
1.25 micrograms/kg BW.h · intraarterial · 90 minAs given in this study (human).
Source sentences
Summary
Likewise, the low dose arterial IGF-I infusion had no effect on blood flow, even though deep venous IGF-I concentrations increased slightly (127 +/- 37 to 172 +/- 19 ng/mL; P = NS).
2 context sentences(design, population, supporting numbers)
Summary · context
Eleven healthy volunteers (10 males and 1 female) underwent brachial arterial and deep forearm venous catheterizations to evaluate the effects of an intraarterial infusion of IGF-I on blood flow.
Summary · context
Saline was infused into the brachial artery for 1 h, followed by infusions of recombinant human IGF-I (1.25, then 10 micrograms/kg BW.h) over 2 subsequent 90-min periods.
Report a problemFND-0802723301
02HumanNon-randomized trialPharmacokinetics
In healthy volunteers, the slight increase in deep venous IGF-I with low-dose infusion was not significant compared with saline control.
In plain wordsIn healthy volunteers, the slight increase in deep venous IGF-I with low-dose infusion was not significant compared with saline control.
Peptide
IGF-1 (mecasermin)
Outcome
No significant changeDeep venous IGF-I
Study
n = 11
Comparator
Saline control
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
1.25 micrograms/kg BW.h · intraarterial · 90 minAs given in this study (human).
Measurements
Deep venous IGF-I
127 ng/mL
before low-dose infusion
Deep venous IGF-I
172 ng/mL
during low-dose infusion (1.25 micrograms/kg BW.h), P = NS
Reported +/- term for deep venous IGF-I
37 ng/mL
before low-dose infusion; uncertainty type not stated
Reported +/- term for deep venous IGF-I
19 ng/mL
during low-dose infusion; uncertainty type not stated
Source sentences
Summary
Likewise, the low dose arterial IGF-I infusion had no effect on blood flow, even though deep venous IGF-I concentrations increased slightly (127 +/- 37 to 172 +/- 19 ng/mL; P = NS).
2 context sentences(design, population, supporting numbers)
Summary · context
Eleven healthy volunteers (10 males and 1 female) underwent brachial arterial and deep forearm venous catheterizations to evaluate the effects of an intraarterial infusion of IGF-I on blood flow.
Summary · context
Saline was infused into the brachial artery for 1 h, followed by infusions of recombinant human IGF-I (1.25, then 10 micrograms/kg BW.h) over 2 subsequent 90-min periods.
Report a problemFND-0802723302
03HumanNon-randomized trialPharmacokinetics
In healthy volunteers, high-dose IGF-I infusion increased deep venous IGF-I approximately 4-fold above control values.
In plain wordsIn healthy volunteers, high-dose IGF-I infusion increased deep venous IGF-I approximately 4-fold above control values.
Peptide
IGF-1 (mecasermin)
Outcome
IncreaseDeep venous IGF-I
Study
n = 11
Comparator
Saline control
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
10 micrograms/kg.h · intraarterial · 90 minAs given in this study (human).
Measurements
Deep venous IGF-I
477 ng/mL
10 micrograms/kg.h infusion
Deep venous IGF-I
150 ng/mL
control
Deep venous IGF-I fold increase
≈ 4 fold
above control values
Reported +/- term for deep venous IGF-I
80 ng/mL
10 micrograms/kg.h infusion; uncertainty type not stated
Reported +/- term for deep venous IGF-I
27 ng/mL
control; uncertainty type not stated
P value for deep venous IGF-I concentration
< 0.0001 unitless
10 micrograms/kg.h infusion versus control
Source sentences
Summary
The 10 micrograms/kg.h infusion rate increased deep venous IGF-I concentrations approximately 4-fold above control values (477 +/- 80 vs. 150 +/- 27 ng/mL, respectively; P < 0.0001)
2 context sentences(design, population, supporting numbers)
Summary · context
Eleven healthy volunteers (10 males and 1 female) underwent brachial arterial and deep forearm venous catheterizations to evaluate the effects of an intraarterial infusion of IGF-I on blood flow.
Summary · context
Saline was infused into the brachial artery for 1 h, followed by infusions of recombinant human IGF-I (1.25, then 10 micrograms/kg BW.h) over 2 subsequent 90-min periods.
Report a problemFND-0802723303
04HumanNon-randomized trialPharmacokinetics
In healthy volunteers, high-dose IGF-I infusion increased peripheral IGF-I approximately 2-fold above control values.
In plain wordsIn healthy volunteers, high-dose IGF-I infusion increased peripheral IGF-I approximately 2-fold above control values.
Peptide
IGF-1 (mecasermin)
Outcome
IncreasePeripheral IGF-I
Study
n = 11
Comparator
Saline control
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
10 micrograms/kg.h · intraarterial · 90 minAs given in this study (human).
Measurements
Peripheral IGF-I
299 ng/mL
10 micrograms/kg.h infusion
Peripheral IGF-I fold increase
≈ 2 fold
above control values
Reported +/- term for peripheral IGF-I
50 ng/mL
10 micrograms/kg.h infusion; uncertainty type not stated
P value for peripheral IGF-I concentration
< 0.0001 unitless
10 micrograms/kg.h infusion versus control
Source sentences
Summary
whereas IGF-I concentrations in the peripheral circulation were increased approximately 2-fold (299 +/- 50 ng/mL) above control values (P < 0.0001).
2 context sentences(design, population, supporting numbers)
Summary · context
Eleven healthy volunteers (10 males and 1 female) underwent brachial arterial and deep forearm venous catheterizations to evaluate the effects of an intraarterial infusion of IGF-I on blood flow.
Summary · context
Saline was infused into the brachial artery for 1 h, followed by infusions of recombinant human IGF-I (1.25, then 10 micrograms/kg BW.h) over 2 subsequent 90-min periods.
Report a problemFND-0802723304
05HumanNon-randomized trialEfficacy outcome
In healthy volunteers, neither IGF-I dose influenced arteriovenous glucose differences compared with saline control.
In plain wordsIn healthy volunteers, neither IGF-I dose influenced arteriovenous glucose differences compared with saline control.
Peptide
IGF-1 (mecasermin)
Outcome
No significant changeArteriovenous glucose difference
Study
n = 11
Comparator
Saline control
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.25 or 10 micrograms/kg BW.h · intraarterial · 90 minAs given in this study (human).
Source sentences
Summary
Arteriovenous glucose differences, peripheral glucose concentrations, and binding protein-3 concentrations were not influenced by either dose of IGF-I.
2 context sentences(design, population, supporting numbers)
Summary · context
Eleven healthy volunteers (10 males and 1 female) underwent brachial arterial and deep forearm venous catheterizations to evaluate the effects of an intraarterial infusion of IGF-I on blood flow.
Summary · context
Saline was infused into the brachial artery for 1 h, followed by infusions of recombinant human IGF-I (1.25, then 10 micrograms/kg BW.h) over 2 subsequent 90-min periods.
Report a problemFND-0802723305
06HumanNon-randomized trialEfficacy outcome
In healthy volunteers, neither IGF-I dose influenced peripheral glucose concentrations compared with saline control.
In plain wordsIn healthy volunteers, neither IGF-I dose influenced peripheral glucose concentrations compared with saline control.
Peptide
IGF-1 (mecasermin)
Outcome
No significant changePeripheral glucose
Study
n = 11
Comparator
Saline control
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.25 or 10 micrograms/kg BW.h · intraarterial · 90 minAs given in this study (human).
Source sentences
Summary
Arteriovenous glucose differences, peripheral glucose concentrations, and binding protein-3 concentrations were not influenced by either dose of IGF-I.
2 context sentences(design, population, supporting numbers)
Summary · context
Eleven healthy volunteers (10 males and 1 female) underwent brachial arterial and deep forearm venous catheterizations to evaluate the effects of an intraarterial infusion of IGF-I on blood flow.
Summary · context
Saline was infused into the brachial artery for 1 h, followed by infusions of recombinant human IGF-I (1.25, then 10 micrograms/kg BW.h) over 2 subsequent 90-min periods.
Report a problemFND-0802723306
07HumanNon-randomized trialMechanism
In healthy volunteers, neither IGF-I dose influenced binding protein-3 concentrations compared with saline control.
In plain wordsIn healthy volunteers, neither IGF-I dose influenced binding protein-3 concentrations compared with saline control.
Peptide
IGF-1 (mecasermin)
Outcome
No significant changeBinding protein-3
Study
n = 11
Comparator
Saline control
Outcome group
Growth hormone and IGF-1 · Metabolic and weight
Studied dose
1.25 or 10 micrograms/kg BW.h · intraarterial · 90 minAs given in this study (human).
Source sentences
Summary
Arteriovenous glucose differences, peripheral glucose concentrations, and binding protein-3 concentrations were not influenced by either dose of IGF-I.
2 context sentences(design, population, supporting numbers)
Summary · context
Eleven healthy volunteers (10 males and 1 female) underwent brachial arterial and deep forearm venous catheterizations to evaluate the effects of an intraarterial infusion of IGF-I on blood flow.
Summary · context
Saline was infused into the brachial artery for 1 h, followed by infusions of recombinant human IGF-I (1.25, then 10 micrograms/kg BW.h) over 2 subsequent 90-min periods.
Report a problemFND-0802723307
08HumanNon-randomized trialEfficacy outcome
In healthy volunteers, high-dose IGF-I was associated with a 68% increase in forearm blood flow versus control.
In plain wordsIn healthy volunteers, high-dose IGF-I increased forearm blood flow by 68% versus control.
Peptide
IGF-1 (mecasermin)
Outcome
IncreaseForearm blood flow
Study
n = 11
Comparator
Saline control
Outcome group
Vascular function · Cardiovascular
Studied dose
10 micrograms/kg.h · intraarterial · 90 minAs given in this study (human).
Measurements
Forearm blood flow
71 mL/min
10 micrograms/kg.h IGF-I
Forearm blood flow
42 mL/min
control
Forearm blood flow increase
68%
10 micrograms/kg.h IGF-I versus control
Reported +/- term for forearm blood flow
8 mL/min
10 micrograms/kg.h IGF-I; uncertainty type not stated
Reported +/- term for forearm blood flow
6 mL/min
control; uncertainty type not stated
P value for forearm blood flow
< 0.0004 unitless
10 micrograms/kg.h IGF-I versus control
Source sentences
Summary
The 10 micrograms/kg.h dose of IGF-I was associated with a 68% increase in forearm blood flow (71 +/- 8 vs. 42 +/- 6 mL/min, respectively; P < 0.0004).
2 context sentences(design, population, supporting numbers)
Summary · context
Eleven healthy volunteers (10 males and 1 female) underwent brachial arterial and deep forearm venous catheterizations to evaluate the effects of an intraarterial infusion of IGF-I on blood flow.
Summary · context
Saline was infused into the brachial artery for 1 h, followed by infusions of recombinant human IGF-I (1.25, then 10 micrograms/kg BW.h) over 2 subsequent 90-min periods.
Report a problemFND-0802723308

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.